ANDA Submissions To US FDA Expected To Decline; Generic User Fees For FY 2019 Will Rise
Executive Summary
FDA's predictions have been pretty consistent; actual submissions haven't been.
You may also be interested in...
GDUFA Sees First-Ever Fee Spending Decrease
Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.
Generic Drug User Fee Program Sees First-Ever Fee Spending Decrease, FTE Decline
Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.
FDA Reports Millions In Unpaid GDUFA Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.